SLC5A2 and congestive heart failure: Adrenergic pathways are also implicated in the beneficial effects of SGLT2 inhibitors for patients with chronic heart failure [73], and may be part of the mechanism of action of cardioprotection by carvedilolin Col4a3-/--129x1/SvJ mice [28].